SK Bio's 2020 Plans Undeterred By Pandemic
US Launch, IPO Moving Ahead
Executive Summary
The CEO of South Korea's SK Biopharmaceuticals talks about commercialization plans, strategy for epilepsy drug cenobamate and other pipeline assets and planned IPO.
You may also be interested in...
Rising COVID-19 Disruption Of Korea's Global R&D
As the prolonged COVID-19 pandemic continues to take a toll globally, South Korean pharma firms’ overseas drug development activities are increasingly being disrupted by the impact.
SK’s Antiepileptic Speeds Japan Entry Via $500m Ono Partnership
Following last year’s license pact with Arvelle in Europe and a US launch earlier this year, SK Biopharmaceuticals’ sizable deal with Ono now paves the way for the South Korean company to enter the Japanese market and further expand antiepileptic cenobamate’s global presence.
SK Biopharm’s Hefty IPO To Support Novel Anti-Epileptic, Pipeline
SK Biopharmaceuticals is pushing ahead with a planned sizable IPO in South Korea in June as it focuses on successfully commercializing novel anti-epileptic drug Xcopri in the US.